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Introduction: Hypoglycaemia is one of the most serious adverse effects of diabetes treatment. Older adults are at 
the highest risk to develop hypoglycaemia. Several studies have established the important positive role of 
educational interventions on achieving glycaemic control and other clinical outcomes, however, there is still a 
lack in studies that evaluate the impact of such type of interventions on hypoglycaemia risk in elderly patients 
with type 2 diabetes. The purpose of this research is to evaluate the effectiveness of pharmacist-led patient 
counselling on reducing hypoglycaemic attacks in older adults with type 2 diabetes mellitus. 
Methods: and analysis: This study is an open-label, parallel controlled randomised trial, which will be conducted 
in the outpatient clinics at the largest referral hospital in the north of Jordan. Participants who are elderly (age 
65 years), diagnosed with type 2 diabetes mellitus, and taking insulin, sulfonylurea, or any three anti-diabetic 
medications will be randomly assigned to intervention (SUGAR Handshake) and control (usual care) groups. 
The SUGAR Handshake participants will have an interactive, individualised, medications-focused counselling 
session reinforced with a pictogram and a phone call at week six of enrolment. The primary outcome measure is 
the frequency of total hypoglycaemic events within 12 weeks of follow up. Secondary outcomes include the 
frequency of asymptomatic, symptomatic, and severe hypoglycaemic events, hypoglycaemia incidence, and time 
to the first hypoglycaemic attack. We will also conduct a nested qualitative study for process evaluation. 
Ethics and dissemination: The Human Research Ethics Committee of the University of Lincoln and the Institutional 
Review Board of King Abdullah University Hospital approved this protocol. The findings of this study will be 
presented in international conferences and published in a peer-reviewed journal. 
Trial registration number: The study protocol has been registered with ClinicalTrials.gov, NCT04081766.   
Introduction 
Background 
Hypoglycaemia is the major limiting factor in diabetes manage-
ment.1 Hypoglycaemia has been found to be associated with cardio-
vascular events such as myocardial infarction, arrhythmias and 
cardiovascular mortality as well as cerebral complications such as 
dementia.2–6 Additionally, hypoglycaemia can impact patients’ quality 
of life.7 Patients with moderate or worse symptoms of hypoglycaemia 
are less satisfied with their treatment and report poorer adherence to 
their medications.8 The great burden of hypoglycaemia is largely 
presented by the considerable health care cost resulting from hospital-
isations, ambulance services, emergency department visits, and absen-
teeism from work.9,10 
Older adults are the most susceptible age group to develop hypo-
glycaemia and to experience hypoglycaemia-related complications.11 
The correlation between ageing and hypoglycaemia in type II diabetes is 
multifactorial.11–15 Factors such as physiological changes in elderly that 
would affect the pharmacokinetics profile of anti-diabetic drugs, 
comorbidities that affect heart and kidneys, nutrition changes and 
cognitive impairment that could affect concordance and compliance 
with treatment regimen.11–15 As the population of older adults is 
increasing, globally; it is expected to see an increase in the prevalence of 
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T2DM in older adults.16,17 
In Jordan, the prevalence of diabetes in people aged 60 years and 
over increased significantly over ten years period.18 It is estimated that 
the number of elderly persons in Jordan will be three times higher in 
2050 than it was in 2017, consequently more older adults will be at risk 
of developing type II diabetes and diabetes-related complications.19 
There are several studies on the association between hypoglycaemia and 
patient characteristics such as patients’ perspectives and attitudes to-
wards diabetes management skills, self-monitoring of blood glucose, and 
non-adherence to anti-diabetic medications in Jordanian pop-
ulation.20–23 However, there is a dearth of data on the interventions that 
could potentially prevent hypoglycaemia in such patients, especially the 
older population. Therefore, it is imperative to develop diabetes-related 
care strategies targeted to this broad population of patients to cope with 
the growing figures in the future. 
In the context of diabetes, pharmacist-led care interventions appear 
to have a pivotal role in glycaemic control, improving self-care activ-
ities, medication adherence, improving quality of life, and reducing 
related complications.24–28 Pharmacist-led care interventions can be 
individualised to each patient to achieve glycaemic control.24,29,30 
However, a few randomised controlled trials (RCTs) have investi-
gated the impact of such interventions on hypoglycaemia in adults 
diagnosed with T2DM.31 Although elderly people are considered 
heterogenous group with different characteristics from younger adults, 
none of these trials has explored the effect of educational interventions 
in this age category. Jordanian pharmacy education equips the phar-
macists with robust clinical knowledge and clinical skills to work with 
other healthcare professionals to provide optimal quality care to the 
patients.32 Therefore, the aim of this study is to evaluate the effective-
ness of pharmacist-led patient counselling on preventing hypoglycaemia 
in older adults with T2DM. 
Educational interventions are considered to be “complex” in-
terventions compared with classic examples of drug interventions in 
RCTs.33 That is an educational interventions’ success or failure could be 
attributed to a myriad of factors besides the interventions’ effectiveness. 
The factors such as the delivery of the intervention, understanding of the 
intervention by the patients and implementation of intervention would 
decide the fate of an educational intervention.34 For this reason, a pro-
cess evaluation is valuable to identify whether an intervention works 
and how, barriers for its implementation, and how to improve it in the 
future.34 Undertaking qualitative studies to evaluate the interventions 
during the implementation stage helps in modifying the ongoing in-
terventions as well as the study design to make them more feasible and 
effective.35 
Objectives 
Primary objective  
● To evaluate the effectiveness of an individualised, pharmacist-led 
educational intervention called (the SUGAR Handshake) in 
reducing hypoglycaemic attacks in older adults with diabetes for a 
duration of 12 weeks. 
Secondary objectives  
● To establish baseline characteristics that could potentially identify 
those elderly patients who are at a higher risk of developing 
hypoglycaemia.  
● To conduct a nested qualitative study as a process evaluation to 
explore contextual factors affecting the implementation and out-
comes of the study. 
Methods 
The methodology of this study is designed, conducted, and reported 
according to the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT)36 and is presented in an appendix to the 
electronic version of this paper. 
Study design 
The study will be a single-centre, two groups, 1:1 parallel, open- 
label, pragmatic randomised controlled trial with a nested process 
evaluation embedded; and will be conducted in two clinics at a referral 
tertiary hospital in Jordan. Participants will be randomly assigned to 
either the intervention group hereinafter referred to as the “SUGAR 
Handshake” group or the control group. Fig. 1 illustrates the detailed 
study flow chart. 
Setting 
This study will be conducted in the endocrinology, cardiology, and 
diabetic foot care clinics at King Abdullah University Hospital (KAUH), a 
referral hospital in the north of Jordan. 
Sample size 
Heterogenous definitions of hypoglycaemia and the frequent un-
derestimation of hypoglycaemic episodes pose some challenges as the 
frequency of hypoglycaemic events is the primary factor in calculating 
the sample size.37,38 We referred to the most relevant study that used a 
similar outcome measure, methodology and intervention to our research 
to calculate the needed sample size.39 The previous study found that the 
mean total number of hypoglycaemic attacks in the control and the 
intervention groups were 5.26  6.5 and 2.58  2.3 per patient in 24 
weeks, respectively. We used the reported frequency of hypoglycaemic 
attacks in both groups to calculate the minimum required sample size. 
Therefore, we need to recruit at least 184 patients to achieve a signifi-
cance level of 0.05 and a study power of 80%.40 Accounting for 10% to 
compensate attrition rate and missing data, the final sample size wished 
to be recruited is 204 participants (102 in each group). 
Participants and recruitment 
We will recruit older adults who are 65 years and above, diagnosed 
with T2DM and being prescribed sulfonylurea, insulin, or any three anti- 
diabetic medications. Exclusion criteria include patients unable to un-
derstand instructions or to give consent, diagnosed with haemolytic 
anaemia or haemoglobinopathies, on palliative care for cancer, with 
advanced-stage or end-stage diseases who are terminally ill, diagnosed 
with psychosis or severe depression, or with life expectancy <6 months, 
impaired mental capacity, unwilling to take home glucose measure-
ments or to use the glucose meter, or unwilling to return for follow up. 
Patients who have a partner or a first-degree relative who has been 
enrolled in the study, are excluded as well. 
We will use two recruitment methods to reach potentially eligible 
patients: an advertisement placed in the reception room where patients 
wait for their appointments, and through direct identification of 
potentially eligible patients at the recruitment sites. HA will be 
responsible for recruiting participants in the endocrinology and diabetic 
foot care clinics meanwhile the research assistant (RA) will recruit from 
the cardiology clinics. HA and the RA will explain the trial purpose and 
processes and provide participant information sheets (supplementary 
file 1) to the interested patients. They will also confirm the eligibility of 
patients who are willing to participate and will ask them to sign a 
written consent form (supplementary file 2). 
Recruitment has started in February 2020 and was suspended in 
March 2020 due to corona virus disease outbreak. Recruitment was 
resumed in June and is expected to be completed in November 2020. 
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Randomisation and allocation 
We will randomly assign participants to the intervention and control 
groups on a 1:1 basis. The random sequence will be generated using the 
website (www.randomization.com) to generate the randomisation 
schedule. Envelopes will be used to conceal the allocation and will be 
opened by the researcher sequentially at the time of each participant’s 
enrolment. The study envelopes will contain the study name, the par-
ticipants’ codes, the group to which the participants are randomised. 
The randomisation sequence and the study envelopes will be prepared 
by a third independent party who will not be involved in the study. The 
envelopes will be closed and opaque and will be given to the researcher 
and the RA who are involved in conducting the study. The envelopes 
that will contain the group allocation will be kept in a locked cabinet in 
the hospital. 
Blinding 
Since this is an open-label study, the patients and the data collectors 
will not be blinded to the assigned group. Eligible patients will be 
informed about the purpose of the study and the study-related activities 
before they sign the consent form. Proper measures will be taken along 
the trial duration to minimise performance and ascertainment bias that 
may result from unblinding participants. 
All participants will be unblinded to the study groups and to the real 
purpose of the trial at the follow-up visit that would mark the end of the 
trial. Additionally, participants who are assigned to the control group 
will receive the SUGAR Handshake intervention at the follow-up visit. 
Fig. 1. Flow chart of participants during the study.  
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Intervention group (SUGAR handshake) 
The educational intervention, the SUGAR Handshake, is designed to 
promote behavioural change to prevent hypoglycaemia. We applied the 
principles of the behaviour wheel theory (BCW)to design the interven-
tion.41 Our educational intervention would enhance the physical and 
psychological capabilities of the patients through improving their 
knowledge and skills in managing and preventing hypoglycaemia. The 
intervention would also lead to the behavioural change by a conducive 
environment to promote behaviour change by addressing the physical 
and cultural needs of the patients. 
We have structured the reporting of the intervention in line with the 
TIDieR (Template for Intervention Description and Replication) check-
list and guide.42 Participants assigned to the SUGAR Handshake group 
will receive individualised counselling regarding hypoglycaemia in 
addition to the usual care provided at the trial sites. The intervention is 
designed by HA who is a pharmacist with prior work experience in pa-
tient counselling and pharmacist-related clinical services. HA has 
trained the RA on delivering the intervention. The intervention is 
delivered in two steps i.e., a face-to-face conversation at the enrolment 
visit followed by a phone call six weeks later. 
Step one: face-to-face conversation at the enrolment visit 
Participants in the intervention group will have a 35–45 min con-
versation with HA/RA to receive the SUGAR Handshake intervention. It 
is designed to meet the physical and cultural needs of the participants 
while considering the individual needs of each participant. To facilitate 
the learning and retaining the information by the elderly, we have 
collated the contents of the intervention under five main domains to 
symbolise a handshake. (See Fig. 2). 
The SUGAR Handshake intervention will cover comprehensive 
strategies to prevent and handle hypoglycaemia with instructions 
related to anti-diabetic medications and managing drug-related prob-
lems. Table 1 illustrates the contents of the SUGAR Handshake inter-
vention about each domain. 
At the end of the face-to-face session, participants will be provided 
with the SUGAR Handshake pictogram containing the main recom-
mendations (Fig. 3). The pictogram is designed to be served as a visual 
reminder of the SUGAR Handshake intervention and as a reference 
throughout the duration of the trial. The fourth and fifth domains of the 
SUGAR Handshake pictogram are designed to allow individualisation of 
the intervention. 
Step Two: Phone call at the 6th PWeek. 
Participants will receive a 20-min follow up call at week six of 
enrolment; so that the first step of the intervention would be reinforced 
as well as participants’ queries/questions would be answered. 
Participants will also be asked about the number and timing of 
having hypoglycaemic attacks during the first six weeks in the trial to re- 
consider modifying the intervention components. 
Control group 
Participants in this group will be offered guidance on hypoglycaemia 
diagnosis and the proper use of the glucose meters in addition to the 
usual care. They will also be provided with instructions on hypo-
glycaemia treatment. As participants in both groups will receive the 
same information regarding hypoglycaemia recognition, they will have 
similar ability to recognise hypoglycaemic attacks. At week 6 of enrol-
ment, participants will receive a phone call to remind them of using the 
glucose meters and documenting hypoglycaemic attacks. 
Of special note, participants who complete the trial duration will 
receive the intervention at the debrief visit and after returning the 
hypoglycaemia diaries. 
Hypoglycaemia documentation 
All participants in both groups will be given glucose meters and test 
strips with a demonstration on proper use to measure their blood glucose 
levels at morning before breakfast daily for 12 consecutive weeks. They 
will also be handed diaries and instructed to document their daily 
fasting blood glucose levels, frequency of experiencing hypoglycaemia 
symptoms, and frequency of severe hypoglycaemic episodes during the 
follow-up period (supplementary file 4 shows the hypoglycaemia di-
aries). Diaries will be collected from participants during their follow up 
visit on the 12th week of their enrolment in the trial. 
Data collection and storage 
Data will be anonymised, encrypted and saved in a password pro-
tected folder on a safe server i.e., using the University of Lincoln’s 
OneDrive with access limited to the research personnel (supplementary 
Fig. 2. Domains of the SUGAR handshake intervention.  
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file 4 shows the data collection form). Electronic data will be maintained 
in storage for a period of 1–3 years after completion of the study. 
Outcome measures 
Primary outcome 
Total hypoglycaemia. Total hypoglycaemia is defined as the number of 
total hypoglycaemic attacks per person per 12 weeks in both groups. 
Total hypoglycaemia will be calculated as the summation of symptom-
atic, asymptomatic, and severe episodes experienced by the participant 
during the follow-up period. More often asymptomatic hypoglycaemic 
events remain undetected; hence they are under-reported. Moreover, 
Hypoglycaemia unawareness is common in elderly T2DM patients.12 
Therefore, we anticipate that the rate of total hypoglycaemia is more 
representative to reporting the effect of the intervention rather than 
considering one type only. 
Secondary outcomes 
Severe, symptomatic, and asymptomatic hypoglycaemia. Types of hypo-
glycaemia are reported separately as the number of episodes per person 
per 12 weeks in both groups (Table 2). We identify types of hypo-
glycaemia in line with the definitions presented by a report of a work-
shop of the American Diabetes Association (ADA) and the Endocrine 
Society.43 We chose this categorisation over others because health care 
professionals mainly follow the ADA guidelines for diabetes manage-
ment in Jordan. Additionally, it is impractical for DM patients to mea-
sure their BG levels frequently to diagnose hypoglycaemia. Hence, it is 
imperative to account for both symptomatic and asymptomatic types of 
hypoglycaemia. 
We will use diaries to measure types of hypoglycaemia and we will 
ask participants to fill in the diary on a daily basis for 12 weeks. Par-
ticipants will be asked to fill in the diary with the date of each day and 
the fasting blood glucose reading. Additionally, they will be asked to tick 
on the boxes for every time they experience severe hypoglycaemia, 
symptoms of hypoglycaemia at the time of fasting blood glucose mea-
surement, and symptoms of hypoglycaemia during the rest of the day. 
Participants will document a symptomatic attack if the symptoms 
resolve after receiving the corrective actions. 
The rate of each type of hypoglycaemia will be measured according 
to the hypoglycaemia diaries filled by the participants. Severe hypo-
glycaemia will be measured directly according to the number of times a 
participant ticks on the diary the boxes that indicate a severe attack. 
Asymptomatic attacks will be measured as the number of times a 
participant records fasting blood glucose of 70 mg/dL or less without 
ticking on the boxes of experiencing symptoms of hypoglycaemia at the 
time of measurement. Symptomatic attacks will be measured as the 
summation of the number of times the participant experiences symp-
toms of hypoglycaemia at the time of fasting blood glucose measurement 
and during the day. 
Proportions of patients experiencing hypoglycaemia. Percentages of pa-
tients experiencing at least one hypoglycaemic attack of any type at 3 
months after randomisation in both groups. 
Time to the first hypoglycaemic attack. Time to experience the first 
hypoglycaemic attack, measured as the number of the day when a 
participant will experience the first hypoglycaemic attack of any type 
after randomisation. 
Process evaluation 
We will carry out a nested qualitative process evaluation in line with 
the Medical Research Council (MRC) framework.44 The process 
Table 1 
Description of the educational contents in the SUGAR Handshake intervention.  
Domain Contents 
Signs and symptoms of hypoglycaemia Recognising hypoglycaemic 
attacks according to 
symptoms 
Understanding the underlying causes of 
hypoglycaemia 
Modifiable factors 
potentiating the risk of 
hypoglycaemia Strategies to 
avoid/minimise these 
factors 
Good glycaemic control and monitoring Self-monitoring of blood 
glucose 
Individualised glycaemic 
targets 
Glucose meter use 
Frequency and timing of 
blood glucose measurements 
Recognising hypoglycaemic 
attacks according to blood 
glucose levels  
Anti-diabetic medications 
Indication and regimen 
Time of administration 
Dosing considerations (e.g. 
dose titration) 
Importance of medication 
adherence and missed 
doses handling 
Method of administration (e. 
g. insulin pens) 
Drug-drug interactions that 
may potentiate the 
hypoglycaemic effect 
lab tests monitoring (e.g. 
kidney function test) 
Storage conditions 
Managing drug-related 
problems 
Lifestyle recommendations 
Regular number and time of 
meals 
Consistent carbohydrate- 
containing food 
Alcohol consumption 
restriction 
Intensive physical activity 
avoidance 
Driving  
Hypoglycaemia and 
hyperglycaemia treatment 
Acknowledgement 
by the patient 
Reassuring patient 
agreement on the 
recommendations  
Patient recall the main 
strategies to recognise, 
avoid, and treat 
hypoglycaemia  
Recap and summary Summarising the 
intervention in 5 main 
points:  
symptoms and blood 
glucose measurement  
causes of hypoglycaemia  
handling antidiabetic 
medications  
lifestyle recommendations  
hypoglycaemia treatment   
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evaluation aims at identifying the contextual factors affecting the 
implementation of the study and the delivery of the intervention, what 
worked and what didn’t, and how the study could be improved in future 
research. 
We will collect qualitative data using semi-structured interviews 
from a handful of participants in each study group. We have prepared 
the interview guide (Table 3) based on the objectives of the study and 
the MRC domains for process evaluation. 
Statistical analyses 
All analysis will be performed on an intention to treat basis. The 
analysis will include all participants randomised regardless of their 
compliance with the study protocol. A secondary per-protocol analysis 
will be conducted including participants who are compliant to 80% or 
more of the study protocol.45,46 The missingness in the primary outcome 
will be handled under the assumption of “missing at random” rather 
than “missing completely at random”, because we are expecting that the 
probability of missing data depends on observed covariates or outcomes 
rather than unobserved data. Therefore, the method chosen to handle 
missing data in the outcomes is multiple imputations.47,48 
Descriptive analysis will be used across randomised groups and 
quantitative analysis will be conducted in RStudio version 3.4.2 (28-9- 
2017).49 Continuous variables will be presented as means, standard 
deviation, median and interquartile range, meanwhile, categorical var-
iables will be presented as frequencies and percentages. The randomised 
groups will be examined and compared for all variables. Categorical 
variables will be evaluated using the chi-square test. Continuous vari-
ables will be tested for normality and based on the distribution of the 
data, appropriate parametric or non-parametric tests will be used. For 
example, paired t-test or Wilcoxon test would be applied to assess the 
differences in baseline variables between both groups and between 
participants who completed the trial as well as the participants who will 
be lost to follow up. 
The primary and secondary outcomes (total and types of hypo-
glycaemic attacks) will be measured across the randomised groups and 
compared using the analysis of covariance (ANCOVA), and the appro-
priate parametric or non-parametric tests dependent on the normality of 
distribution. Subgroup analysis will also be performed using interaction 
terms in regression models. 
Fig. 3. SUGAR handshake pictogram.  
Table 2 
Definitions of hypoglycaemia types.  
Type of 
Hypoglycaemia 
Definitiona 
Severe  - requiring the assistance of another person to administer 
carbohydrate and glucagon or take any other corrective 
actions  
- accompanied by neurological recovery after the corrective 
actions 
Symptomatic  - presence of typical symptoms such as sweating, dizziness, 
light-headedness, tremor, hunger, headache  
- presence or absence of plasma glucose concentration 70 
mg/dL (3.9 mmol/L) 
Asymptomatic  - absence of typical symptoms  
- measured plasma glucose concentration 70 mg/dL (3.9 
mmol/L)  
a According to the ADA guidelines. 
Table 3 
Interview schedule.  
1. Introduction 
You have previously read in the participant information sheet that we are 
conducting a phone interview as a part of this study and you accepted to participate 
in it. Therefore, I would like to ask you some questions about your experience with 
the study processes that have been provided to you at the inclusion visit. The 
information will help us in improving several aspects of the study. The interview 
should take about 10 min. Are you available to respond to the questions at this time? 
2. I would like to start by asking: how do you describe your participation in the study 
so far? If needed, the interviewers may explain the question by the follow-up 
question: How do you rate your participation in the study from good to poor and 
why? 
3. What has worked for you from the study processes that you were asked to do? 
– why do you think they have? 
what hasn’t worked for you from the study processes that you were asked to do? 
- why do you think they haven’t? 
4. From your perspective, how the study could be improved? Please consider any 
aspects of the study that you think could be improved. 
5. At the end, I would like to thank you for taking part in this interview. If you have 
any questions or concerns, please contact me on my mobile number provided in the 
participant information sheet.  
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We will use logistic regression analysis to examine associations be-
tween the categorical outcome variable (frequent vs infrequent hypo-
glycaemia episodes) and independent variables such as sex, age, 
educational level, living arrangements, duration of diabetes, number of 
current medications, experiencing previous hypoglycaemia, the status of 
self-monitoring of blood glucose, types of anti-diabetic medications, 
baseline HbA1c and interactions between the independent variables. 
The findings will be also presented as odds ratio and 95% confidence 
intervals. A P value of less than 0.05 will be considered statistically 
significant. Hypoglycaemia rates will be described with Kaplan-Meier 
survival curves, considering the time to the first hypoglycaemic attack 
as the outcome measure.50 
Qualitative data analysis 
The interviews will be audio-recorded then transcribed and trans-
lated into the English language. We will use the thematic analysis 
approach to analyse the collected data for process evaluation.51 
Patient and public involvement 
The SUGAR Handshake intervention was designed by the researchers 
as a result of HA’s previous experience in counselling the target popu-
lation in Jordan about hypoglycaemia. Patients contributed in shaping 
the intervention by reporting feedback on the instructions that helped 
them the most to avoid hypoglycaemic attacks; which were mainly 
related to anti-diabetic medications. Furthermore, consultation of the 
health care providers working at the trial site played a role in the study 
design (schedule of follow up visits and recruitment rate). 
Ethics and dissemination 
Ethical approval and trial registration 
The study protocol has been approved by the Human Research Ethics 
Committee of the University of Lincoln, United Kingdom (approval 
number: 2019–0170) and the Institutional Review Board of KAUH, 
Jordan (approval number: 13/3/1376). The ROSE-ADAM study was 
registered at clinicaltrial.gov (NCT04081766). 
Protocol amendments 
An ethics amendment for Version 5 of the protocol was approved in 
June 2020. If it is found there is a need for protocol amendments 
through the embedded evaluation process, the changes will be discussed 
by the supervisory team and will be communicated in writing to the 
Human Research Ethics Committee of the University of Lincoln and the 
Institutional Review Board of KAUH. 
Dissemination of findings 
Upon completion of the study, we will provide the trial site with an 
executive summary of the findings in the form of a report. Participants 
would be able to get the results of the study from their health care 
professionals at the trial site no later than one year after the end of data 
collection. We are planning to disseminate the study outcomes through 
peer-reviewed publications and presentations in conferences. We will 
comply with the authorship eligibility guidelines of the International 
Committee of Medical Journal Editors. 
Discussion 
This pragmatic RCT will be the first to determine the effectiveness of 
a pharmacist-led educational intervention, the SUGAR Handshake, to 
reduce events of hypoglycaemia for elderly adults with T2DM, with 
embedded process evaluation. The impact of educational interventions 
on controlling hypoglycaemia in patients diagnosed with T2DM has 
been inconclusive. That is some studies have shown positive results, 
meanwhile, others have failed to show such results.39,52–56 Elderly 
patients are considered underrepresented age group and they are usually 
excluded from clinical trials about diabetes.57 Studies which assessed 
the effectiveness of educational interventions on hypoglycaemia in pa-
tients with T2DM have either excluded elderly patients or included them 
with the young adult age groups.39,52–56 This study specifically in-
vestigates the effect of counselling on older adults with T2DM. 
A major strength of this trial is the SUGAR Handshake components. 
The intervention is designed to be simple and tailored to the needs of 
elderly patients. Furthermore, this intervention adopts patient-centred 
approach in individualising instructions and shared-decision making 
with the participants based on their needs. Implementing this approach 
has proven to improve clinical outcomes, disease management, and 
controlling hypoglycaemia among patients with diabetes.58,59 
The SUGAR Handshake intervention is designed to be pragmatic and 
to facilitate transferability of evidence into practice. Therefore, phar-
macists can easily deliver it to the patients in different working positions 
including hospitals and community pharmacies. Moreover, the delivery 
of the SUGAR Handshake intervention is cheap and will not cost an extra 
burden on patients. Previous studies concerning the attitudes, religious 
beliefs, and self-management skills amongst patients with T2DM helped 
in assuring the appropriateness of contextual and cultural delivery as 
well as the implementation of the study and the SUGAR Handshake 
intervention.20  23Using blood glucose/hypoglycaemia diaries to objec-
tively report and measure several types of hypoglycaemia is another 
strength. This will facilitate a more accurate measurement of hypo-
glycaemic events where the concern that patients may forget to report 
the experienced episodes is reduced. 
A plausible limitation that warrants consideration is the short follow 
up duration (12 weeks), which may make it difficult to examine the 
sustainability of the intervention effect. However, we anticipate that this 
duration will decrease the dropout rate. Moreover, we expect the effect 
of our intervention to last up to at least six months as concluded by a 
previous trial.39 Another concern is the enrolment of relatives into 
different groups upon randomisation, which will introduce contamina-
tion bias. Therefore, if a patient happens to have a relative who has 
already participated in the trial, he would be excluded. Additionally, 
participants may not fully adhere to the intervention during the 
follow-up period. For this reason, they will receive a phone call reminder 
at week six of enrolment. Individualising the intervention according to 
each patient’s lifestyle and potential causes of hypoglycaemia will 
enhance the adherence to the intervention as well. 
As this is an open-label study, performance bias and ascertainment 
bias may result from unblinding participants and the data collectors, 
respectively. Participants in the control group may be less adherent to 
the trial protocol and more likely to withdraw from the trial. However, 
efforts will be made to standardise the trial protocol, frequency and time 
of follow up, and treatment of experienced hypoglycaemia across both 
groups to minimise performance bias. We also anticipate that the 
objective measurement of the outcomes would minimise ascertainment 
bias. 
The prevalence of diabetes in Jordan has been growing rapidly to 
reach 23.7% in 2017.60 In light of the lack of awareness regarding dia-
betes diagnosis, causes, and management we would expect a further 
increase in the number of Jordanians who are diagnosed with diabetes 
and who would suffer from diabetes-related complications.20,60 While 
pharmacists are easier to access than physicians, a possible strategy to 
mitigate the burden of diabetes is to establish and support the 
pharmacist-led, patient-oriented services.61 
We speculate that the findings of this trial may be valuable to pa-
tients with diabetes, pharmacists, health care professionals, pharmacy 
students, and health organisations nationally, regionally, and globally. 
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